Odonate
Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated
to the development of best-in-class therapeutics that improve and extend
the lives of patients with cancer, today announced financial results for
the three months ended March 31, 2019.

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Newmont Mining Corporation (NYSE:NEM), Johnson & Johnson (NYSE:JNJ), Portola...

Odonate
Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated
to the development of best-in-class therapeutics that improve and extend
the lives of patients with cancer, today presented results of
preclinical studies of tesetaxel, Odonate’s investigational, orally
administered taxane, at the American A

Odonate
Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated
to the development of best-in-class therapeutics that improve and extend
the lives of patients with cancer, today announced the initiation of
CONTESSA TRIO, a multi-cohort, multicenter, Phase 2 study of tesetaxel,
Odonate’s investigational,

Odonate
Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated
to the development of best-in-class therapeutics that improve and extend
the lives of patients with cancer, will present at the Cowen and Company
39th Annual Health Care Conference on Wednesday, March 13, 2019, at 8:40
a.m. Eastern Time.

Odonate
Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated
to the development of best-in-class therapeutics that improve and extend
the lives of patients with cancer, today announced that it has initiated
CONTESSA 2, a multinational, multicenter, Phase 2 study of tesetaxel,
Odonate’s investigational

Odonate
Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated
to the development of best-in-class therapeutics that improve and extend
the lives of patients with cancer, today announced the acceptance for
presentation at the American Association for Cancer Research (AACR)
Annual Meeting 2019 of an abst

Odonate
Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated
to the development of best-in-class therapeutics that improve and extend
the lives of patients with cancer, today announced financial results for
the three and twelve months ended December 31, 2018.

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Omnicom Group Inc. (NYSE:OMC), Venator Materials PLC (NYSE:VNTR),...

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Senior Housing Properties Trust (NASDAQ:SNH), NACCO Industries, Inc....

Odonate
Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated
to the development of best-in-class therapeutics that improve and extend
the lives of patients with cancer, today announced financial results for
the three and nine months ended September 30, 2018.

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), AxoGen, Inc. (NASDAQ:AXGN),...

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ballard Power Systems, Inc. (NASDAQ:BLDP), Reading International Inc...

Odonate
Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated
to the development of best-in-class therapeutics that improve and extend
the lives of patients with cancer, today announced financial results for
the three and six months ended June 30, 2018.

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Helen of Troy Limited (NASDAQ:HELE), Macro Bank Inc. (NYSE:BMA), American...

Odonate
Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated
to the development of best-in-class therapeutics that improve and extend
the lives of patients with cancer, today announced that results from a
multicenter Phase 2 study of tesetaxel, administered orally as a single
agent to patients with HER

Odonate
Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated
to the development of best-in-class therapeutics that improve and extend
the lives of patients with cancer, today announced that it will present
at the Jefferies 2018 Global Healthcare Conference on Wednesday,
June 6, 2018, at 2:30 p.m. Easte

Odonate
Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated
to the development of best-in-class therapeutics that improve and extend
the lives of patients with cancer, today announced that there will be
two poster presentations on tesetaxel at the 2018 American Society of
Clinical Oncology (ASCO) Annu

Odonate
Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated
to the development of best-in-class therapeutics that improve and extend
the lives of patients with cancer, today announced financial results for
the three months ended March 31, 2018.

NEW YORK, April 10, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ericsson (NASDAQ:ERIC), Toronto Dominion Bank (NYSE:TD),...

NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Odonate Therapeutics, Inc. (NASDAQ:ODT), Greenlight Reinsurance,...

Odonate
Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated
to the development of best-in-class therapeutics that improve and extend
the lives of patients with cancer, today announced financial results for
the three and twelve months ended December 31, 2017.

Odonate
Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated
to the development of best-in-class therapeutics that improve and extend
the lives of patients with cancer, today announced that it has initiated

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company
dedicated to the development of best-in-class therapeutics that improve
and extend the lives of patients with cancer, today announced the
closing of its initial public offering of 6,250,000 shares of common
stock at a public offering price of $24.00 per share. The aggregate
gross proceeds from the initial public offering to Odonate were
approximately $150 million, before deducting underwriting discounts and
commissions and offering expenses. The shares began trading on the

Odonate Therapeutics, Inc. (the Company or Odonate), a pharmaceutical
company dedicated to the development of best-in-class therapeutics that
improve and extend the lives of patients with cancer, today announced
the pricing of its initial public offering of 6,250,000 shares of common
stock at a public offering price of $24.00 per share for aggregate gross
proceeds of approximately $150 million. All of the shares of common
stock are being offered by Odonate. In addition, Odonate has granted the
underwriters a 30-day option to purchase up to 937,5